ASHA Workers in Mysuru Protest Over Delayed Payments and Reduced Incentives
Accredited Social Health Activists (ASHA workers) in Mysuru staged a demonstration demanding payment of pending honorariums and incentives, citing delays of several months from both Central and State governments. The workers also protested against reduced incentives due to deactivation of services in the ASHA Nidhi software and increased workload. The protest highlights financial hardship among frontline health workers and raises questions about the sustainability of India's community health worker program.
Members of the Karnataka State United ASHA Workers' Association staged a protest in Mysuru on Wednesday, submitting a memorandum to the Chief Executive Officer of the Zilla Panchayat. The workers reported that Central government incentives for two months and State government honorariums for two months remain unpaid, creating financial difficulties. The association also objected to the Health and Family Welfare Department's decision to deactivate nine services in the ASHA Nidhi software, which could reduce monthly incentives by up to ₹1,000 per worker. Additional grievances included delays in payments under tuberculosis, TBI, and non-communicable disease initiatives, excessive performance evaluations, and excessive digital data-entry work. The workers demanded implementation of the Chief Minister's January 2025 announcement guaranteeing a minimum monthly remuneration of ₹10,000, a ₹1,000 increase in honorarium to match other health workers, and retirement benefits for retired ASHA workers.
What's missing
The article does not provide the government's response to these demands or official explanation for the payment delays and service deactivations.
What different sources said
- The HinduCenter
Pending dues, incentive cuts trigger ASHA workers’ protest in Mysuru
Related
Sydney Psychiatrist Retains Medical License After Sexual Assault Conviction
Gopi Ilawala, a Sydney psychiatrist convicted of sexually assaulting an intoxicated colleague in 2022, has been allowed to continue practicing medicine despite the state health regulator seeking to have his registration cancelled. The New South Wales Civil and Administrative Tribunal reprimanded him and imposed conditions rather than striking him off, citing his remorse, lack of prior convictions, and support from two senior psychiatrists. The decision raises questions about professional accountability and public protection in medical regulation.
Australia's TGA to crack down on illegal peptides; government allocates $100m for arthritis research
Australia's Therapeutic Goods Administration has announced a crackdown on illegal peptides due to a surge in imports and online advertising, designating them a priority focus area. The federal government has simultaneously committed $100 million to medical research into arthritis prevention, diagnosis, and treatment. These developments reflect growing regulatory concerns about unregulated drugs and increased investment in chronic disease research.
GLP-1 Drugs Like Ozempic May Help ADHD Symptoms, According to Patient Reports and Clinical Observations
Social media users and some patients are reporting that GLP-1 receptor agonist drugs like Ozempic appear to improve ADHD symptoms, including increased focus, reduced procrastination, and better impulse control. GLP-1s were originally developed to treat Type 2 diabetes but are being studied for various other conditions. While anecdotal reports are growing, no formal clinical trials are currently testing these drugs specifically for ADHD, and the mechanism behind any potential benefit remains unclear.